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1. INTRODUCTION {#cam41735-sec-0005}
===============

Androgen deprivation therapy (ADT) occupies an important position in the treatment of prostate cancer and is used as a main treatment for prostate cancer of all stages.[1](#cam41735-bib-0001){ref-type="ref"}, [2](#cam41735-bib-0002){ref-type="ref"}, [3](#cam41735-bib-0003){ref-type="ref"} In general, ADT is achieved by surgery, drug‐based monotherapy, or combined androgen blockade (CAB).[3](#cam41735-bib-0003){ref-type="ref"}, [4](#cam41735-bib-0004){ref-type="ref"}, [5](#cam41735-bib-0005){ref-type="ref"}, [6](#cam41735-bib-0006){ref-type="ref"}

ADT results in a marked decrease in the prostate‐specific antigen (PSA) level and shows a good tumor reduction effect in most cases.[7](#cam41735-bib-0007){ref-type="ref"} However, the PSA may be found to gradually increase even when the testosterone value is at a castration level. Such biochemical relapse is called castration‐resistant prostate cancer (CRPC).[8](#cam41735-bib-0008){ref-type="ref"}, [9](#cam41735-bib-0009){ref-type="ref"}, [10](#cam41735-bib-0010){ref-type="ref"} There are several definitions of CRPC, but the current guidelines do not take into consideration use of anti‐androgens up to CRPC.[8](#cam41735-bib-0008){ref-type="ref"}, [9](#cam41735-bib-0009){ref-type="ref"}, [10](#cam41735-bib-0010){ref-type="ref"}

For this reason, it is necessary to recognize two important points concerning CRPC. First, CRPC patients have various treatment histories. Thus, at the time of CRPC determination, patients may have different tumor biological properties. Second, the relationship between the type of ADT and the period from treatment start to CRPC (time to CRPC) has not been sufficiently studied. If there were a big difference in the time to CRPC depending on the type of ADT, then the type of ADT would be an important factor when considering the entire course of treatment of prostate cancer.

These matters are of little concern if endocrine therapy is being carried out by either method alone. Looking at the positioning of ADT as the first‐line main treatment in Western guidelines, ADT itself is not listed as a treatment option for localized cancer, and they go no further than indicating the possibility that CAB is slightly useful for advanced cancer.[9](#cam41735-bib-0009){ref-type="ref"}, [10](#cam41735-bib-0010){ref-type="ref"} However, in reality, according to a paper based on an observational study, CAB was selected for 46% of prostate cancer patients in the US CaPSURE registry and for 59% to 74% in Japanese studies.[2](#cam41735-bib-0002){ref-type="ref"}, [3](#cam41735-bib-0003){ref-type="ref"}, [5](#cam41735-bib-0005){ref-type="ref"} Formerly, the overall survival (OS) was employed as the primary endpoint in studies of the usefulness of CAB that were conducted before the 2000s, when excellent CRPC therapeutic drugs came into use. However, considering that the survival period after CRPC has been significantly extended by the use of new drugs,[11](#cam41735-bib-0011){ref-type="ref"}, [12](#cam41735-bib-0012){ref-type="ref"}, [13](#cam41735-bib-0013){ref-type="ref"}, [14](#cam41735-bib-0014){ref-type="ref"}, [15](#cam41735-bib-0015){ref-type="ref"} we have reached a point where it is necessary to focus on the treatments administered up to CRPC and revisit the question of the optimal ADT method.

This study investigated the optimal method for ADT with the aim of solving some of the current problems confronting treatment of prostate cancer.

2. PATIENTS AND METHODS {#cam41735-sec-0006}
=======================

2.1. Patients {#cam41735-sec-0007}
-------------

We used a data set from a Japanese multi‐institutional registry prepared by the Japan Study Group of Prostate Cancer consisting of 17 388 patients (almost all patients were Japanese) who started ADT as the first‐line main treatment between 1 January 2001 and 31 December 2003. This database includes the follow‐up patient status up to 31 September 2014, when the data were locked. Approval of data collection was obtained by the institutional review board. All the data were anonymized so as to protect the identities of subjects. Among all registered patients, 1009 patients treated with anti‐androgen monotherapy and another 2605 patients who started CAB with an anti‐androgen other than bicalutamide and flutamide were also excluded because the drugs were selected for unusual conditions or are rarely used nowadays.[2](#cam41735-bib-0002){ref-type="ref"}, [9](#cam41735-bib-0009){ref-type="ref"} Thus, the remaining 13 774 patients were the subjects of this study.

2.2. Methods {#cam41735-sec-0008}
------------

The characteristics of tumors were determined by each physician in the usual clinical practice framework, basically according to the Japanese guideline.[16](#cam41735-bib-0016){ref-type="ref"} Then, the clinical TNM stages were determined according to the UICC 5th edition,[17](#cam41735-bib-0017){ref-type="ref"} and Gleason scores were determined according to the 1977 version.[18](#cam41735-bib-0018){ref-type="ref"} Prostate cancer risks were determined by the J‐CAPRA scoring system, consisting of the initial PSA, Gleason score, and TNM category.[19](#cam41735-bib-0019){ref-type="ref"} The type of primary ADT was classified as monotherapy (surgical or medical castration) or CAB (surgical or medical castration plus a nonsteroidal anti‐androgen), as described in our earlier paper.[5](#cam41735-bib-0005){ref-type="ref"} The data set used was derived from the real world, so the treatment was not randomly selected, and had been decided by the patient and/or physician.

2.3. Analysis of survival {#cam41735-sec-0009}
-------------------------

Diagnosis of progression was performed by each physician, basically depending on the aforementioned guideline.[16](#cam41735-bib-0016){ref-type="ref"} This guideline defined two types of progression: PSA progression and clinical progression. PSA progression was defined as three consecutive PSA re‐rises following PSA decrease by ADT under a low testosterone level in response to ADT. The first date of consecutive PSA rise was defined as the PSA progression date. Clinical progression was defined as regrowth of a tumor or development of a new lesion. For analysis of the progression‐free survival (PFS), either type of progression, or death, caused by the prostate cancer was defined as an event. For analysis of the OS, death due to any cause was considered an event. For analysis of the cancer‐specific survival (CSS), only death due to the prostate cancer was considered an event. Patients without any event were censored at the last follow‐up visit. The number of days from initial hormonal manipulation to the earliest date of these events or the censored date was calculated for analyses. The median follow‐up duration estimated by the reverse Kaplan‐Meier method was 3.7 years.

2.4. Statistical analysis {#cam41735-sec-0010}
-------------------------

Correlations between the clinicopathological background and the type of ADT were tested using the Cochran‐Armitage trend test and a logistic regression model. The survival rate was estimated by the Kaplan‐Meier method, and survival differences between different groups were examined by the log‐rank test. The hazard ratio of each variable was calculated using Cox\'s proportional hazard model. The propensity score, that is, the probability of CAB use, was calculated using a logistic regression model in which potential confounders, that is, age, TNM category, initial PSA value, and Gleason score, were used as independent variables, and the type of ADT was used as the dependent variable. One‐to‐one propensity score‐matched pairs were selected from the two treatment groups by nearest neighbor matching. An open‐source software, R version 3.3.3,[20](#cam41735-bib-0020){ref-type="ref"} was used for statistical analyses. All tests were two‐sided, and a *P*‐value of \<0.05 was considered statistically significant.

3. RESULTS {#cam41735-sec-0011}
==========

3.1. Background characteristics {#cam41735-sec-0012}
-------------------------------

Table [1](#cam41735-tbl-0001){ref-type="table"} shows the patient characteristics. The median patient age was 75 years (interquartile range (IQR), 71‐80). A total of 6225 (45.2%) patients had organ‐confined disease, while 2514 (18.3%) and 4359 (31.6%) patients had clinical stage III and stage IV disease, respectively.

###### 

Background characteristics according to the type of androgen deprivation therapy

  Characteristic             Total (no.)   Monotherapy (no.)   CAB (no.)   CAB% (%)   *P*‐value
  -------------------------- ------------- ------------------- ----------- ---------- -----------
  Total                      13 774        5395                8379        60.8       
  Age at diagnosis (y)                                                                \<0.001
  70                         3233          1029                2204        68.2       
  \>70 and ≤75               3850          1408                2442        63.4       
  \>75 and ≤80               3711          1599                2112        56.9       
  \>80                       2980          1359                1621        54.4       
  PSA at diagnosis (ng/mL)                                                            \<0.001
  ≤20                        6200          2858                3342        53.9       
  \>20 and ≤100              4290          1579                2711        63.2       
  \>100 and ≤500             2017          612                 1405        69.7       
  \>500                      1267          346                 921         72.7       
  Gleason score                                                                       \<0.001
  2 to 6                     4212          1896                2316        55.0       
  7                          3497          1451                2046        58.5       
  8 to 10                    4287          1405                2882        67.2       
  Not available              1778          643                 1135                   
  T category                                                                          \<0.001
  T1                         2899          1387                1512        52.2       
  T2                         4493          1868                2625        58.4       
  T3                         5038          1714                3324        66.0       
  T4                         1291          399                 892         69.1       
  Not available              53            27                  26                     
  N category                                                                          \<0.001
  N0                         11 141        4552                6589        59.1       
  N1                         1926          532                 1394        72.4       
  Not available              707           311                 396                    
  M category                                                                          \<0.001
  M0                         9749          4159                5590        57.3       
  M1                         3525          1013                2512        71.3       
  Not available              500           223                 277                    
  Clinical stage                                                                      \<0.001
  I to II                    6225          2844                3381        54.3       
  III                        2514          963                 1551        61.7       
  IV                         4359          1285                3074        70.5       
  Not available              676           303                 373                    
  J‐CAPRA risk category                                                               \<0.001
  Low risk                   5156          2454                2702        52.4       
  Intermediate risk          4129          1442                2687        65.1       
  High risk                  1924          517                 1407        73.1       
  Not available              2565          982                 1583                   

CAB, combined androgen blockade; CI, confidence interval.
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With respect to the type of ADT, monotherapy and CAB were used in 5395 (39.2%) and 8379 (60.8%) patients, respectively. The type of the first castration was medical castration in 12 598 patients (91.4%; leuprolide and goserelin in 8577 and 4021 patients, respectively) and surgical castration in 1176 patients (8.5%). The first anti‐androgen used in the CAB group was bicalutamide 80 mg in 7202 patients (86.0%) and flutamide in 1177 patients (14.0%).

3.2. Type of androgen deprivation therapy according to background characteristics {#cam41735-sec-0013}
---------------------------------------------------------------------------------

The proportion of patients treated by CAB became significantly higher as patient age became significantly younger and the tumor risk became higher (*P* \< 0.001, Table [1](#cam41735-tbl-0001){ref-type="table"}). Multivariate analysis using a logistic regression model revealed that younger age, higher PSA value at diagnosis, higher Gleason score, and nodal or distant metastasis were positively associated with CAB use (Table [2](#cam41735-tbl-0002){ref-type="table"}).

###### 

Background characteristics accounting for the type of androgen deprivation therapy

  Characteristic             Category   Odds ratio for CAB use                                                 
  -------------------------- ---------- ------------------------ ----------- --------- ----------- ----------- ---------
  Age at diagnosis (y)       ≤70        1.8                      (1.6‐2.0)   \<0.001   1.7         (1.5‐1.9)   \<0.001
  \>70 and ≤75               1.5        (1.3‐1.6)                \<0.001     1.5       (1.3‐1.7)   \<0.001     
  \>75 and ≤80               1.1        (1.0‐1.2)                0.039       1.2       (1.1‐1.3)   0.004       
  \>80                       Ref                                             Ref                               
  PSA at diagnosis (ng/mL)   ≤20        Ref                                            Ref                     
  \>20 and ≤100              1.5        (1.4‐1.6)                \<0.001     1.3       (1.2‐1.5)   \<0.001     
  \>100 and ≤500             2.0        (1.8‐2.2)                \<0.001     1.5       (1.3‐1.7)   \<0.001     
  \>500                      2.3        (2.0‐2.6)                \<0.001     1.4       (1.1‐1.7)   0.001       
  Gleason score              2 to 6     Ref                                            Ref                     
  7                          1.2        (1.1‐1.3)                0.002       1.0       (0.9‐1.1)   0.714       
  8 to 10                    1.7        (1.5‐1.8)                \<0.001     1.3       (1.2‐1.4)   \<0.001     
  T category                 T1         Ref                                            Ref                     
  T2                         1.3        (1.2‐1.4)                \<0.001     1.1       (1.0‐1.2)   0.066       
  T3                         1.8        (1.6‐2.0)                \<0.001     1.1       (1.0‐1.3)   0.054       
  T4                         2.1        (1.8‐2.4)                \<0.001     1.0       (0.8‐1.2)   0.879       
  N category                 N0         Ref                                            Ref                     
  N1                         1.8        (1.6‐2.0)                \<0.001     1.2       (1.0‐1.3)   0.043       
  M category                 M0         Ref                                            Ref                     
  M1                         1.8        (1.7‐2.0)                \<0.001     1.4       (1.3‐1.6)   \<0.001     
  Clinical stage             I to II    Ref                                                                    
  III                        1.4        (1.2‐1.5)                \<0.001                                       
  IV                         2.0        (1.9‐2.2)                \<0.001                                       
  J‐CAPRA risk category      Low risk   Ref                                                                    
  Intermediate risk          1.7        (1.6‐1.8)                \<0.001                                       
  High risk                  2.5        (2.2‐2.8)                \<0.001                                       

CAB, combined androgen blockade; CI, confidence interval; Ref, reference.
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3.3. Survival rates according to clinical stages {#cam41735-sec-0014}
------------------------------------------------

The PFS rate was 58.3% (95% confidence interval (CI), 57.3% to 59.5%) at 5 years (75.9%, 63.2%, and 30.4% for clinical stage I to II, III, and IV, respectively; *P* \< 0.001). The CSS rate was 87.7% (87.0% to 88.5%) at 5 years (75.9%, 63.2%, and 30.4% for clinical stage I to II, III, and IV, respectively; *P* \< 0.001). The OS rate was 76.6% (75.7% to 77.6%) at 5 years (75.9%, 63.2%, and 30.4% for clinical stage I to II, III, and IV, respectively; *P* \< 0.001).

3.4. Survival rates according to the type of androgen deprivation therapy {#cam41735-sec-0015}
-------------------------------------------------------------------------

### 3.4.1. Propensity score matching and survival in matched patients {#cam41735-sec-0016}

Due to the aforementioned results that younger patients and patients at higher risk tended to receive CAB more frequently (Tables [1](#cam41735-tbl-0001){ref-type="table"} and [2](#cam41735-tbl-0002){ref-type="table"}), we concluded that the two treatment groups were not comparable and that imbalanced background variables act as confounding factors if we simply compare the survival between the two treatment groups. We therefore performed propensity score matching to achieve comparability. A total of 11 209 patients with no missing data included 8826 matched patients (Figure [1](#cam41735-fig-0001){ref-type="fig"}A). The backgrounds of the matched patients were well balanced (Figure [1](#cam41735-fig-0001){ref-type="fig"}B). Before matching, survival was similar (PFS and OS) or significantly better (CSS) in the monotherapy group. However, after controlling the backgrounds, the PFS rate was significantly higher in the CAB group compared with the monotherapy group (65.6% and 59.6% at 5 years, respectively; time to progression, 11.6 vs 7.1 years; hazard ratio in the CAB group, 0.78 (95% CI, 0.72 to 0.84, *P* \< 0.001) (Figure [1](#cam41735-fig-0001){ref-type="fig"}C). Likewise, CSS and OS were significantly higher in the CAB group (Figure [1](#cam41735-fig-0001){ref-type="fig"}C).

![Background characteristics and survival rates of patients treated by monotherapy or combined androgen blockade before and after propensity score matching. A, Distribution of propensity scores for CAB use in monotherapy and CAB groups before and after propensity score matching. After matching (right), the distribution of the propensity scores in each treatment group became similar. B, Background characteristics in monotherapy and CAB groups before and after propensity score matching. Before matching, patients treated with CAB were characterized by being significantly younger and having higher risk factors (left). However, after matching, there were no differences in background characteristics between the two treatment groups (right). C, Survival rates before and after propensity score matching. After matching, the PFS rate was significantly higher in favor of CAB (right). Numbers below the graph represent patient numbers at risk. CAB, combined androgen blockade; NR, not reached to median](CAM4-7-4893-g001){#cam41735-fig-0001}

### 3.4.2. Subgroup analysis {#cam41735-sec-0017}

We further compared the PFS in the two treatment groups within each background strata. As shown in Figure [2](#cam41735-fig-0002){ref-type="fig"}, the PFS rate was significantly higher in the CAB group compared with the monotherapy group in all risk subgroups except for those with the highest risk factors (PSA exceeding 500 ng/mL, T4, N1 or M1 disease, and J‐CAPRA high‐risk category).

![Progression‐free survival (PFS) according to the type of androgen deprivation therapy within subgroups. A higher PFS rate was demonstrated in the CAB group in all risk subgroups except for extremely high‐risk categories. Horizontal lines in the hazard ratio represent 95% confidence interval. CAB, combined androgen blockade; NR, not reached to median; CI, confidence interval; PFS, progression‐free survival](CAM4-7-4893-g002){#cam41735-fig-0002}

4. DISCUSSION {#cam41735-sec-0018}
=============

The data set we used was derived from the real world, and selection of the type of ADT was not randomized. In fact, in the data used, as in an independent report,[2](#cam41735-bib-0002){ref-type="ref"} CAB was more frequently selected for cases with high‐risk factors and young cases. Meta‐analyses showed that the OAB was better with CAB by nonsteroidal anti‐androgen than with monotherapy during the time period from 2001 through 2003, when the patients were registered in the database.[21](#cam41735-bib-0021){ref-type="ref"} There is a possibility that this may have influenced selection of the type of ADT. This type of imbalance is widely known as "confounding by indication."[22](#cam41735-bib-0022){ref-type="ref"}, [23](#cam41735-bib-0023){ref-type="ref"} We used propensity score matching to control for confounding factors in this study.[24](#cam41735-bib-0024){ref-type="ref"} As a result, the CAB showed significantly better results in terms of each of the PFS, CSS, and OS. Also, in subgroup analysis, the CAB group showed a better PFS in most subgroups, except for some subgroups with high‐risk factors.

Our present results suggest that it is possible to select the type of ADT according to the risk of prostate cancer. In J‐CAPRA low‐risk cases, the CAB group showed a significantly better PFS, and it can be thought that CAB was a reasonable choice. However, low‐risk cases showed a good PFS in excess of several years even with monotherapy, so monotherapy may be adequate for some patients. In intermediate‐risk cases, the CAB group also showed a time to progression that was 43.9% longer than in the monotherapy group, so CAB can again be considered to have been a reasonable choice. Today, CRPC therapeutic drugs are 10 to 20 times more expensive than the conventional nonsteroidal anti‐androgens, so if you extend the time to progression by 10% to 5%, respectively, medical expenses at the time of CRPC in the CAB group can be reduced. Choosing CAB can thus be considered reasonable in terms of the cost, as well. On the other hand, in J‐CAPRA high‐risk cases, for whom ADT is generally indicated, CAB did not improve the PFS. Therefore, magnitude of clinical significance of ADT including CAB might be limited in this risk group, and a stronger treatment is required. Recent studies tested docetaxel or abiraterone in combination with first‐line ADT for advanced prostate cancer and showed prolongation of both the OS and the time to progression in the combination group.[25](#cam41735-bib-0025){ref-type="ref"}, [26](#cam41735-bib-0026){ref-type="ref"}, [27](#cam41735-bib-0027){ref-type="ref"} Therefore, as NCCN Guidelines mention,[10](#cam41735-bib-0010){ref-type="ref"} combined use of docetaxel or abiraterone from the beginning of ADT should be considered for these patients.

The problem exposed by our present study is the ambiguity of the definition of CRPC. Currently, the definition of CRPC in various guidelines is re‐elevation of the PSA value even though the testosterone level is low, while the use or nonuse of anti‐androgens is not considered.[8](#cam41735-bib-0008){ref-type="ref"}, [9](#cam41735-bib-0009){ref-type="ref"}, [10](#cam41735-bib-0010){ref-type="ref"} However, this study\'s finding that the time to progression varies greatly depending on the type of ADT is important. This is because the biological properties of the tumors differ between the CAB group and the monotherapy group even though the cases were uniformly judged to be CRPC. As an example, in the STRIVE trial comparing enzalutamide and bicalutamide 50 mg for nonmetastatic and metastatic CRPC patients, bicalutamide caused the PSA to decline in one‐third of CRPC patients who had been naïve to bicalutamide.[28](#cam41735-bib-0028){ref-type="ref"} Based on that finding, it can be thought that we need to modify the definition of CRPC by incorporating the history of use of anti‐androgens, or, in the absence of such modification, we need to clarify the use or nonuse of anti‐androgens and then conduct various investigations. Accordingly, if we were to evaluate the "time from ADT to CRPC" and the "time from CRPC to death" individually, then we would be able to perform more detailed analyses of prostate cancer treatments\' contents and the treatment course. We think this approach is essential for devising a sequential strategy for prostate cancer drug therapy for the future.

This study has a number of limitations. One is that the TNM and Gleason score classification methods used were different from the current versions.[8](#cam41735-bib-0008){ref-type="ref"}, [16](#cam41735-bib-0016){ref-type="ref"} A second is that the main endpoint, that is, progression, was judged by individual urologists based on diagnostic criteria that were current at the time. A third is that our database did not include detailed information concerning use of anti‐androgens midway through the treatment course. A fourth is that almost all the patients in this data set were Japanese, so that the findings obtained in the present study might be specific to Japanese and might be different in other ethnic groups. Moreover, the data used for the study were derived from the real world, so the type of ADT was not randomized; however, we attempted to eliminate confounding factors by propensity score matching. On the other hand, our study employed data for more patients than in similar studies published to date. Also, the study cohort included prostate cancer patients of all stages, not just advanced cancer, and the patients were close to actual clinical cases. We think these advantages provide sufficient value, even in view of the above limitations.

In conclusion, this study used propensity score matching and found that the PFS, CSS, and OS were better in the CAB group compared with the monotherapy group. In particular, the difference in the PFS due to the type of ADT type was remarkable, and the utility of CAB was widely shown, except for in some high‐risk subgroups. As the prognosis after progression to CRPC has improved in recent years due to various new drugs, it is now time to reevaluate our treatment strategies up to CRPC. The findings generated in this study show the feasibility of selection of the type of the first‐line ADT (castration monotherapy vs castration plus nonsteroidal anti‐androgen vs castration plus new drugs) according to the risk and also show that the type of ADT is, in itself, an important clinical factor. Therefore, it might be worthwhile to reconsider the definition of CRPC based on the presence or absence of anti‐androgen use up to progression.
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